Oral acyclovir at a dose of 800 mg five times daily for seven days was compared with placebo in a randomised double blind trial conducted at three centres in the United Kingdom. The study group comprised 205 elderly immune competent patients suffering from herpes zoster who were entered within 72 hours of the onset of rash. Acyclovir significantly reduced the times to arrest of new lesion formation (p=0.005), loss of vesicles (p<0-001), and full crusting (p=0-02) in those patients entered within 48 hours of the onset of rash. In addition, there was a significant reduction in pain during treatment with acyclovir as compared with placebo (p=0-008). Of the patients with severe pain on entry, 40% (10/25) of those treated with acyclovir had no or only mild pain at the end of treatment, whereas in the placebo group all had residual moderate or severe pain (p<0-001). No clinically important adverse effects of acyclovir were reported.
Introduction
Herpes zoster is a common disease occurring predominantly in the elderly and is often associated with severe pain in the acute phase and with profound and protracted postherpetic neuralgia. Antiviral treatment offers a logical approach to reducing pain by inhibiting viral replication and hence reducing tissue damage. Double blind placebo controlled studies have shown acyclovir at doses of 5 mg/kg or greater eight hourly intravenously for five days to modify the development of rash and reduce acute pain'' and topically applied acyclovir to control ocular manifestations.4 Oral treatment, however, is more practical for herpes zoster, as most patients do not require hospital management. About 15-20% of acyclovir taken by mouth is absorbed. Peterslund et al using an oral dose of400 mg five times daily for five days did not find significant differences compared with intravenous acyclovir (5 mg/kg eight hourly for five days) in the treatment of herpes zoster, though the number of patients in their study was small and only patients with a history of rash and prodrome of less than 96 hours were included. A double blind placebo controlled study using the same oral dosing regimen of acyclovir showed a significant reduction in days of new lesion development within the affected dermatome in the acyclovir group, though differences in other characteristics did not achieve statistical significance.6 Acyclovir 800 mg four hourly by mouth has been shown to give mean steady state peak and trough concentrations of 7-5 and 4-5 tmol/l (0-17 and 0-10 mg/100 ml) respectively (unpublished findings), which are in excess of the median effective dose (ED50) of most strains of varicella zoster virus and may be a more rational dosage regimen for herpes zoster infections.
Double blind placebo controlled studies of 800 mg acyclovir five times daily for seven days were therefore initiated at three centres within the United Kingdom (Sheffield, Birmingham, and Southampton) using a common protocol. The trial was designed to determine the efficacy of oral acyclovir in the acute stage of herpes zoster.
Patients and methods
We studied immune competent patients of either sex, aged 60 The times to observed changes in characteristics of the rash were analysed using the Mantel-Cox (log rank) test. Survival curves of rash progression were estimated by the Kaplan-Meier technique. Variables of rash progression were analysed using one tailed tests. The changes in pain severity scores between day 0 and day 6 and the distribution ofthe pain scores on day 6 were analysed using Mann-Whitney U tests.
Results
Two hundred and nine patients entered the study and were randomised to the treatment groups. Four were subsequently withdrawn for the following reasons. One patient (case 12; acyclovir, Birmingham) suffered vomiting attacks after both the first and second doses on day 0; in case 14 (placebo, Birmingham) the patient's condition worsened, requiring admission for intravenous acyclovir after three days; in case 28 (acyclovir, Birmingham) there was a violation ofprotocol (at one stage 21 tablets had been taken in less than 24 hours); and one patient (case 89; acyclovir, Sheffield) was diagnosed as not suffering from zoster. Thus 205 subjects were available for analysis, of whom 96 were from Sheffield, 62 from Birmingham, and 47 from Southampton. The groups were comparable for sex and age; duration of prodrome; severity, distribution, and duration of rash; and severity of pain (table I) .
PROGRESSION OF RASH
Acyclovir was associated with significantly accelerated healing when treatment was started within 48 hours of the onset of rash (table II) . Treatment begun between 48 and 72 hours resulted in no significant differences between the two treatment groups, though there were trends in favour of acyclovir (table II) . Small differences in numbers of patients Patients were assessed by the research nurse on entry (day 0), daily to day 7, and then every other day to day 13 or until all lesions had crusted. Further follow up was continued at weekly intervals until day 28 and then monthly for a further five months or until all pain had stopped, when patients were discharged. On entry the patient's age, sex, duration of prodrome, and duration of rash were noted. The extent and distribution of the rash were scored according to the number of discrete lesions in the dermatome (0=none, 1=<25, 2=26-50,3=51-100, 4=>100) and details of the appearance of the lesions were recorded (macule/papule, vesicle/pustule, ulceration, or crust). Scores of 3 and 4 were regarded as severe and 2 moderate. The severity of pain was recorded by the patient on a linear visual analogue scale of 0-100% ranging from "none" to "very severe. " For analysis this was converted to nil=0, 1-24%=1, 25-75%=2, and 76-100%=3. Patients were also asked to give a pain score from 0 to 10, each reflected occasional lack of data on specific observation. Analysis of rash progression in all patients who had herpes zoster affecting the ophthalmic division of the trigeminal nerve showed no apparent significant differences between acyclovir and placebo (table III). There were too few patients with ophthalmic zoster to stratify according to duration of rash before the start of treatment.
ACUTE PAIN
Analysis of average daily pain scores for change in pain from day 0 (baseline) to day 6 (last 24 hours of treatment) using the 0-3 scoring system showed a highly significant reduction in the acyclovir group compared with placebo (p=0008) (table IV). Analysis using the 0-10 scoring system also showed a significant reduction in the acyclovir treated group (p=0 03). The figure plots the average daily pain scores for both groups during the acute phase of the study. Significance was maintained in the subgroups of patients with moderate or severe pain at entry. Table V shows the distribution of pain scores at day 6 related to pain score on entry. Forty per cent of patients (10/25) with a score of 3 on entry who received acyclovir had a score of 0 or 1 at day 6 compared with none in the placebo group (p<0001).
Adverse events were recorded in 12 patients in the acyclovir group and 1531 significant improvement has occurred during the treatment period.' This might be explained on the basis that viral replication may persist beyond five days, and a seven day period of treatment was therefore used. An alternative explanation may be that acyclovir has some intrinsic analgesic properties.
In this study patients treated with acyclovir had significantly enhanced rates of resolution of rash and, more importantly by, a significant reduction in pain scores during the period of treatment. This was most noticeable in patients with a pain score of 3 at entry, 13 in the placebo group. These included 10 reports of gastrointestinal symptoms in the acyclovir group and nine in the placebo group and three neurological events (headache, tremor, giddiness) in the acyclovir group compared with eight in the placebo group (headache (two patients), hallucinations (one), shaking (one), giddiness (two), confusion (two)). Haematological and biochemical safety data showed no adverse effects of treatment.
Discussion
Intravenous acyclovir has been shown to have a significant effect on the development of rash and acute pain in herpes zoster.'3 The oral route of administration is the most practical way to take acyclovir for most patients, and this study has attempted to define whether 800 mg acyclovir five times daily for seven days is an effective regimen. Studies with lower doses56 have not been associated with consistent benefit and the 800 mg dose appears to be satisfactory from pharmacokinetic data (unpublished findings). Patients treated for five days have been noted in some instances to develop a post-treatment exacerbation of pain even though a 40% of whom (10/25) had a score of 0 or 1 by the end of acyclovir treatment, compared with those who received placebo, all of whom still had a pain score of 2 or 3 at day 6. Regression in pain, however, did not appear to continue after stopping acyclovir (figure). It This study has shown that oral-acyclovir may modify the course of acute herpes zoster and reduce pain. This benefit was most pronounced in patients who began treatment within 48 hours-of the onset of rash. In addition, pain relief was particularly noticeable in those with the most severe pain. Acyclovir 800 mg five times daily appears to be a suitable regimen, though better absorbed preparations should allow lower dosage regimens to be employed. It appears that a seven day course is preferable to a five day course of treatment.-The effect of this regimen on postherpetic neuralgia is not known, but studies are continuing.
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